|
FABRY DISEASE
DEFINITION:
A lysosomal storage disorder characterized by the accumulation of lipid (glycosphingolipid) in peripheral tissues resulting in the triad of acroparesthesia, angiokeratomas, and corneal opacities.
EPIDEMIOLOGY:
 incidence: over 300 cases reported
 age of onset:
 late childhood -> adolescence
 risk factors:
 familial - x-linked recessive with complete penetrance but variable phenotype
 chrom.#: Xq22
 gene: alpha-galactosidase A
 M only
PATHOGENESIS:
1. Background
 alpha-galactosidase A catalyzes the conversion of trihexosylceramide to dihexosylceramide
 the alpha-galactosidase gene has been cloned
 disease originally described by Fabry in 1898
2. Genetic Defect
 genetic defect -> deficiency of alpha-galactosidase A activity -> accumulation of three glycosphingolipids in peripheral tissues:
 trihexosylceramide - in the endothelium of blood vessels and is the major cause of pathology
 digalactosylceramide - accumulate in the heart & kidneys
 blood group B-1 - increase the progression of the disglycolipid ease in those with type B blood group
CLINICAL FEATURES:
1. Neurological Manifestations
1. Peripheral Nervous System
1. Acroparesthesia
 burning pain crises of the extremities
 onset in childhood
 may be the initial manifestation of the disease
 crises
 periodic and excruciating
 may become more frequent and severe with age then lessen in the 2nd or 3rd decades
 precipitated by heat, cold, exercise, humidity, fever, and/or fatigue
 last from several hours to days
 usually associated with a low-grade fever and elevated ESR
 burning or tingling sensation beginning in the fingers and toes and spreading proximally
2. Central Nervous System
 cerebral vascular disease with ischemia and infarction in cortical and brainstem areas -> strokes, seizures, person-ality changes, and hemiplegia
 no mental retardation
2. Cutaneous Manifestations
1. Angiokeratomas
 small dark purple-blue telangiectasia
 may appear in childhood but usually not noted until after
 10 years of age
 most dense between the umbilicus and knees with propensity for umbilicus and buttocks
 progressive increase in the size and number with age
 do not blanch with pressure
2. Others
 hypohidrosis
 lymphedema of the legs
3. Ocular Manifestations
1. Cornea
 linear/whorling opacities originating from a central vortex
 also have lenticular opacities
2. Lens
 cataracts
3. Retina
 dilated and tortuous retinal vessels with aneurysmal dila-tation
 papilledema +/- hypertensive changes
4. Respiratory Manifestations
 chronic airflow obstruction
 dyspnea
5. Cardiac Manifestations
 conduction defects
 hypertension
 ischemic heart attacks
 mitral valve insufficiency
 thromboses
6. Gastrointestinal Manifestations
 abdominal and/or flank pain
 diarrhea
 hepatomegaly
 nausea and vomiting
7. Renal Manifestations
 proteinuria eventually leading to end stage renal failure (ESRF) between the 2nd and 4th decades
8. Musculoskeletal Manifestations
 permanent deformity of the distal interphalangeal joint of the fingers
 avascular necrosis of the head of the femur or talus with limp, knee pain, and/or hip pain
9. Endocrine Manifestations
 short stature
 delayed puberty
INVESTIGATIONS:
1. Diagnosis
 deficiency of alpha-galactosidase activity in WBC's or cultured skin fibroblasts
 mild corneal opacities in 80% of obligate heterozygotes
 prenatal
 deficiency of alpha-galactosidase activity in cultured chorionic villi or amniocytes
2. Serum
 elevated trihexosylceramide
 mild microcytic hypochromic anemia
 abnormal renal function (ESRF)
3. Urine
 elevated trihexosylceramide - WBC's and casts
 lipid inclusions with characteristic - isosthenuria birefringent "Maltese crosses"
 proteinuria +/- hematuria
4. EKG
 left ventricular hypertrophy - T-wave inversion
 ST segmental changes - short PR interval
5. Pathology
1. Biopsy
 lipid accumulation in:
 kidneys - epithelial & endothelial cells of glomeruli and tubules
 airways - airway epithelium
MANAGEMENT:
1. Supportive
 no treatment available for disease
 multidisciplinary approach
 Paediatrics, Neurology, Dermatology, Ophthalmology, Cardio-logy, Nephrology, Endocrinology
 painful crises treated with low dose diphenylhydantoin or carbamazepine
 renal transplant for ESRF
2. Prognosis
 mean age of survival is 42 years
 death from ESRF or vascular disease of the heart or CNS
|